Unoprostone in Phase III study for RP

Article

Unoprostone will begin patient enrolment for the Phase III clinical study for the treatment of retinitis pigmentosa (RP), claims the latest press release.

Unoprostone will begin patient enrolment for the Phase III clinical study for the treatment of retinitis pigmentosa (RP), claims the latest press release.

The UF-021 ophthalmic solution will undergo a randomized, double-masked controlled study for 52 weeks to assess efficacy on 180 patients. An additional open trial study on the safety of unoprostone will be conducted for a further 52 weeks at 38 sites.

Dr Yukihko Mashima, president of R-Tech Ueno, commented, "A Phase I clinical study with Unoprostone ophthalmic solution was completed in 2008, and a Phase II clinical study was completed in February 2010. As a result, promising results were obtained leading to an increase in the number of the patients whose central retina sensitivity improved."

"I am very glad that the first registration of the last stage, a Phase III clinical study, has been reached now," continued Dr Mashima. "This study will be conducted with the strong support of many ophthalmologists, the patients and their family in addition to the governmental support of the Japan Science and Technology Agency (JST). R-Tech Ueno will make best efforts to rapidly complete the registration and to deliver this new therapeutic drug to the many patients who have long awaited this treatment."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.